疾病篩檢理論與成本效益分析及其政策規劃
Disease screening theory,cost benefit analysis and planning
| 節 | 週三 |
|---|---|
5 13:20–14:10 | 疾病篩檢理論與成本效益分析及其政策規劃 YN613 2 節連堂 |
6 14:20–15:10 |
* 根據陽明交大上課時間表所列
授課內容包括疾病篩檢的理論架構與成本效益分析及案例探討,分述如下: 1.理論架構:疾病自然病史、疾病篩檢對象、篩檢工具的選擇、陽性個案篩選標準與轉介確診、疾病治療的存活、疾病篩檢決策與倫理觀點 2.成本效益分析:篩檢成效評估、篩檢成本估計、篩檢成本效益分析、決策分析 3.案例探討:癌症篩檢(子宮頸癌、大腸癌、乳癌、口腔癌、胃癌、肺癌)、心血管疾病篩檢、新生兒聽力篩檢、傳染病篩檢(結核病、愛滋病) This teaching prgram includes the theoretical framework of disease screening, cost-effectiveness analysis and case study. which are described as follows: 1. Theoretical framework: natural history of disease, disease screening population, choice of screening tools, screening criteria for positive cases and referring for confirming diagnosis, survival of screening detected patients, screening decision-making and ethical viewpoints. 2. Cost-effectiveness analysis: screening effectiveness estimation, screening cost estimation, decision analysis 3. Case studies: cancers screening (cervical cancer, colorectal cancer, breast cancer, oral cancer, gastric cancer, lung cancer), cardiovascular diseases screening, neonatal hearing screening, infectious diseases screening (tuberculosis, AIDS)
疾病篩檢為疾病三段預防的第二段,可以有效降低疾病的發生率與死亡率,在我國疾病防治政策中,也經常運用疾病篩檢的策略,推動各項防治工作。而疾病篩檢有其理論架構,涉及合適的篩檢對象、篩檢方法、確診方式及治療成效等考量因素,如何規劃出符合成本效益的篩檢政策,需有堅實的理論基礎。透過課程的學習,讓同學了解疾病篩檢的理論架構及其成本效益之推估,並就國內外疾病篩檢政策進行分析探討,能提出優缺點論述及具體政策規劃及建議。Disease screening is the secondary prevention of disease in the public health intervention program, which can effectively reduce the incidence and mortality of specific diseases. In the national disease prevention and control policies, screening strategies are often used in various diseases prevention and management programs. Planning the disease screening programs, It is necessary to understand theoretical framework, suitable population for screening, screening test tools, disease diagnosis methods, and early treatment efficacy. Through this lesson, students can learn the theoretical framework of disease screening and its cost-effectiveness analysis and how to criticize and propose advantages and disadvantages of disease screening policies from different countries. as well as how to make a well disease screening policy.
課堂作業書面及口頭報告(30%) 期末分組口頭報告(30%)及書面報告(30%) 課堂中對上課內容的提問及回答(10%) paper and oral reports(30%) team oral report (30%) and paper report (30%) Questions and answers in the classroom(10%)
| 週次 | 主題 |
|---|---|
| 第 1 週 | 校慶停課一天 School day, No class課程介紹及疾病防治策略簡介 Introduction of lesson and disease prevention |
| 第 2 週 | 課程介紹及疾病防治策略簡介 Introduction of lesson and disease prevention疾病自然病史與篩檢(一) Disease and natural history and screening(1) |
| 第 3 週 | 疾病自然病史與篩檢 Disease and natural history and screening疾病自然病史與篩檢(二) Disease and natural history and screening(2) |
| 第 4 週 | 篩檢方法(一) Screening tools(1) |
| 第 5 週 | 篩檢方法(二) Screening tools(2) |
| 第 6 週 | 篩檢成效評估(一) Efficacy evaluation of screening program(1) |
| 第 7 週 | 篩檢成效評估(二) Efficacy evaluation of screening program(2) |
| 第 8 週 | 篩檢成本效益分析(一) Cost-effectiveness of screening program(1) |
| 第 9 週 | 篩檢成本效益分析(二) Cost-effectiveness of screening program(2) |
| 第 10 週 | 疾病篩檢之決策分析(一) Decision of disease screening(1) |
| 第 11 週 | 疾病篩檢之決策分析(二) Decision of disease screening(2) |
| 第 12 週 | 疾病篩檢之實務操作(一) The practice of Screening program(1) |
| 第 13 週 | 疾病篩檢之實務操作(一) The practice of Screening program(1) |
| 第 14 週 | 國內外疾病篩檢成效與檢討(一) The effectiveness and comment of National disease screening programs(1) |
| 第 15 週 | 國內外疾病篩檢成效與檢討(二) The effectiveness and comment of National disease screening programs(2) |
| 第 16 週 | 分組報告-疾病篩檢政策(一) Team final oral report of disease screening program(1) |
| 第 17 週 | 分組報告-癌症篩檢(二) Team final oral report of disease screening program(2) |
| 第 18 週 | 學生參訪整合式篩檢 visiting the integrated screening activity in the community |
1. Screening: Evidence and Practice 1st edition (2007 Oct); Author: Angela E Ruffle, J. A. Muir Gray 2. Quantitative Methods Evaluation of Cancer Screening 1st edition (2001 Aug); Author: Steven W Duffy, Catherine Hill, Jacques. 3. Word Cancer Report 2014; Editors: Burnard W. Steward, Cristopher P. Wild. IARC WHO.